Abivax Stock Soars 36% After Trial Update Eases Cancer Concerns
Abivax NASDAQ:ABVX shares jumped as much as 36% after its latest obefazimod trial update helped calm investor concerns that cancer could be a possible side effect of the biotech's key experimental ulcerative colitis drug. The company said cancer cases reported in the study were within a background…